Download Condition of animals with superficial bladder cancer after

O.G. Kostyuk, B.A Bolyuh, G.Y. Kostyuk, V.G. Kostyuk, O.O. Konovalyuk
Condition of animals with superficial bladder cancer after submucosal administration of
chemotherapy.
The problem of superficial bladder cancer fails to excite scientists around the world. The
complexity of the etiology and pathogenesis, a large variability in clinical presentation, a variety
of morphological forms, the presence of severe complications that often lead to disability and
often lethal outcomes, these all allow us to consider the issue relevant to our time and unsolved.
On the surface localization of the tumor in the mucosa and submucosa of urinary bladder
indicates the bulk of the literature. Thus, some authors state that approximately 75-80% of all
patients with the initially diagnosed cancer of the urinary bladder the tumor locates superficially
(Tis, Ta, T1), in other cases it is determined by the germination of the tumors in the muscle
membrane of the urinary bladder and lymph glands.
The experiments were conducted on the 15 outbred, opposite-sex, mature dogs.
At the creating the models of cancer all animals didn’t have any significant changes in
behavior, receiving food, without changes in blood parameters, satisfactorily carried 6-10-month
feeding with β-naftilaminom. All animals, after its use on the surface layer of the bladder have
single or multiple tumors. The 12 animals (80%) have the presence of multicentric growth of
cancerous tumors. The research of urine was conducted for some occult blood (azopiromov test)
and the research of urine cytology all of these were done to use the submucosal administration of
doxorubicin and mitomycin-C, with the purpose to form drug depots in the submucosa, in the
case of the surgical intervention. The results of these studies were used to determine the initial
changes in the epithelium of the urinary bladder and to prevent tumor invasion into the muscle
membrane.
The received data showed that during the usage of β-food naftilaminu the initial number
of leukocytes, and the number of leukocytes before the operative intervation, were not
significantly changed for the whole period of the feeding. That is, a significant impact on the
overall condition of the animals in the case of the usage of this drug is not observed. Typical that
there was a slight leukocytosis in the early days of the postoperative period. The number of
leukocytes remained elevated compared with initial values, and even on the third day. Two
weeks later, leukocyte count gradually decreased and approached to the normal state. The
gradual reduction of their number after submucosal administration of chemotherapy was
observed up till eight weeks of the study, with the following normalization of peripheral blood
leukocytes. In ten weeks, it corresponded to the initial value.
The observations of much longer period (in one and two years) showed that the number
of leukocytes in peripheral blood swung in the range of the norm. The indicator of red blood
cells changed in different way. At the early stages of observation, from the beginning of feeding
with β-naftilaminu to the operative intervation on urinary bladder, the number in this group of
animals was close to normal. After submucosal administration of chemotherapy in the first 3
days the red blood cells were significantly elevated to the initial values. In more remote period
their number gradually decreased.
To two animals after ingestion of β-naftilaminu in submucosa the chemotherapy is not
administered. They served as a comparative group, who were not carried out the treatment
anticancer drugs. These animals in 3-4 months after discontinuing use of β-naftilaminu with
food were observed the changes in behavior in the form of reduced activity (most of the time the
dogs were lying, they had a weak reaction on the nickname and sound stimulus, decreased the
amount of food which they ate) . The both animals were paid attention with a significant
decrease of the body weight. One animal died in 6 months, the second animal died in 10 months
after discontinuing the use of β-naftilaminu. No specific treatment affected adversely the
condition of animals.
Conclusions.
1. The use of β-naftilamin leads to the development of tumors of urinary bladder is
created superficial bladder cancer model that allows us to track the process of recovery of the
animals in the application of a method of treatment of superficial bladder cancer.
2. Lack of specific antitumor treatment leads to the fatal consequences.
3. The animals after submucosal administration of chemotherapy in the later periods of
leukocytes and erythrocytes in the peripheral blood ranged norm.
4. The behavior of animals and their feed consumption in submucosal administration
0,0125% chemical solution in terms of distance, does not differ from those in intact dogs.